Navigation Links
Clinical Trial Volunteers Uneasy About Some Financial Ties
Date:4/11/2008

They were least surprised when researchers got paid but more upset when they owned stock

FRIDAY, April 11 (HealthDay News) -- Many volunteers in clinical studies aren't overly concerned if researchers have financial conflicts, but there is some loss of trust, suggests a U.S. study.

"Though peoples' willingness to take part in a hypothetical clinical trial did not suffer substantially based on the types of financial disclosures, and many of our study respondents were still likely to say that they would participate despite researchers' financial interests, we captured a sense of unease about some financial ties -- particularly owning company stock -- that did affects peoples' attitudes and trust in clinical research," Dr. Jeremy Sugarman, a professor at the Johns Hopkins Berman Institute of Bioethics and The Johns Hopkins School of Medicine, said in a prepared statement.

"We need to keep this in mind as we determine how best to disclose acceptable financial interests to fully inform potential study participants," Sugarman said.

He and colleagues at Duke University and Wake Forest University sent a description of a hypothetical clinical drug trial to 3,623 adults with asthma or diabetes. Each description included one of five different financial disclosures.

One said the study leader might benefit financially from the study, one said the study leader would be reimbursed only for trial-related expenses, one said the study leader receives extra money from the drug company for activities such as consulting and speaking, one said the study leader holds stock in the drug company, and one said the researcher's institution holds stock in the drug company.

More than two-thirds of the participants said they weren't surprised that the researcher or institution might benefit financially from the clinical trial. Respondents were least surprised to learn that researchers received a per capita payment, and most surprised to learn the researcher owned stock in the drug company.

While 59 percent of respondents said the possibility of financial benefit for the researcher or institution didn't change their trust, 36 percent said their trust was diminished when they read the financial disclosure.

"A disclosure that the researcher received per capita payments was least likely to change respondents' level of trust whereas as disclosure that the researcher held an equity interest was most likely to reduce trust," the study authors wrote.

The study was published online April 2 in the Journal of General Internal Medicine.

"Ties between companies and physicians who do research with them are becoming more transparent, but it's been unclear how well this information is understood by the public and to what extent they influence people who consider enrolling in clinical trials," Sugarman said. "Our study offers some of the first clear insights on the impact of disclosures of this information."

More information

The U.S. National Institutes of Health has more about clinical trials.



-- Robert Preidt



SOURCE: Johns Hopkins Medicine, news release, April 4, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: